SDHA and neoplasm: Interestingly, in vitro and in vivo studies have demonstrated a profound anti-tumor efficacy and selectivity of shikonin (an anti-metabolic compound) towards SDHA overexpressing ovarian tumor cells, superior to that observed with chemotherapy [20].